A replay of the corporate presentation will be available on the Events section of the company’s investor relations website.

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

A Columbia-led study uncovers how gliomas cause seizures and cognitive impairments by disrupting brain activity. Using ...

A groundbreaking immunotherapy is showing unprecedented success against one of the deadliest childhood brain cancers — ...

Chimerix stock surges 324% in three months following NDA submission for high-grade glioma drug, dordaviprone, for accelerated ...

A study led by Dr. Peter Canoll's lab, in collaboration with researchers at Columbia University Irving Medical Center, ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company advancing targeted antitumor virotherapies, will host an invest ...

An analysis of adults with malignant glioma revealed that men were diagnosed at a younger age and women had worse ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, reported a ca ...

In connection with the SEPA executed in December 2023 and amended in January 2024, Calidi was granted the option to sell up to $25 million of common stock over a three-year period, subject to certain ...

A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University, has succeeded in the diagnosis ...

Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas by Detection of H3F3A K27M Mutation in Circulating Tumor DNA ...